Optimal JIT, CTCA to speed-up patient enrolment in cancer trials

17th July 2019 (Last Updated July 17th, 2019 14:42)

Global contract research organisation PPD’s Accelerated Enrollment Solutions (AES) business unit Optimal just-in-time (JIT) has entered into a partnership with Cancer Treatment Centers of America (CTCA).

Optimal JIT, CTCA to speed-up patient enrolment in cancer trials
Optimal Just-in-Time and Cancer Treatment Centres of America are collaborating to speed patient enrolment in oncology clinical trials. Credit: Esther Dyson.

Global contract research organisation PPD’s Accelerated Enrollment Solutions (AES) business unit Optimal just-in-time (JIT) has entered into a partnership with Cancer Treatment Centers of America (CTCA).

The collaboration aims to accelerate patient enrolment in oncology clinical trials and improve patient’s access to life-changing treatments.

It will also help save time for drug researchers in their pursuit to defeat cancer.

CTCA is a cancer care network of hospitals and outpatient care centres in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa.

Integrating the CTCA managed sites with Optimal JIT approach has enabled cancer patients to enter trials faster and allowed AES clients to reduce the time needed for starting the trial.

The approach was successful in reducing site activation time from a maximum of eight months to a minimum of two weeks.

Data generated by CTCA shows results that exceed traditional sites on the same trials when analysing data currency, query rates, and retention.

PPD Optimal service offerings chief operating officer Krystyna Kowalczyk said: “Our collaboration with CTCA demonstrates how we are changing the paradigm of cancer care.

“Together, we are creating meaningful opportunities for cancer patients to participate in clinical trials and access innovative therapies close to home, allowing them to receive care within the context of their support networks in their own communities.

“Some 30% of the patients we enrol with CTCA are from under-represented populations, which reflect our goal of expanding clinical trial opportunities more broadly. Our goal is to enrol more patients from fewer sites in less time to support important oncology trials.

“Thanks to our JIT methodology, a two-week turnaround for first-patient-in is now possible.”